Arrowhead Pharmaceuticals Inc
ARWR
NASDAQ
Biotechnology
$86.64
USD
+1.05 (+1.23%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $12.21B
Volume 817.8K
Revenue
$669.50M
TTM
+16.8%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-272.13M
TTM
-70.8%
YoY
Operating Cash Flow
$-59.05M
TTM
-370.3%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 |
|---|---|---|---|---|---|
Revenue | 27.8 | 256.5 | 264.0 | 73.7 | 75.3 |
YoY Growth | — | — | +10461.3% | -86.4% | +171.0% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 27.8 | 256.5 | 264.0 | 73.7 | 75.3 |
Selling, General & Administrative | 30.9 | 37.7 | 46.0 | 41.7 | 47.1 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 193.3 | 212.4 | 223.2 | 215.0 | 245.3 |
Operating Income | -165.6 | 44.1 | 40.8 | -141.3 | -170.1 |
EBITDA | -159.3 | 50.5 | 47.2 | -134.9 | -163.4 |
Other Income / Expense | -0.2 | 4.7 | 0.3 | 10.7 | -1.2 |
Total Other Income / Expense | -13.5 | -8.0 | -12.5 | 3.7 | -8.8 |
Income Before Income Taxes | -179.1 | 36.1 | 28.3 | -137.6 | -178.9 |
Income Taxes | -0.4 | 20.0 | 0.0 | 0.0 | 0.0 |
Net Income | -178.7 | 16.1 | 28.2 | -137.6 | -178.9 |
Consolidated Net Income / Loss | -178.7 | 16.1 | 28.2 | -137.6 | -178.9 |
Net Income Attributable to Common Shareholders | -175.2 | -23.8 | 30.8 | -132.7 | -194.3 |
Basic EPS | -$1.26 | -$0.17 | $0.22 | -$0.93 | -$1.36 |
Diluted EPS | -$1.26 | -$0.17 | $0.22 | -$0.93 | -$1.36 |
Basic Shares Outstanding | 139.0M | 137.8M | 137.0M | 142.4M | 143.4M |
Diluted Shares Outstanding | 139.0M | 136.7M | 140.7M | 142.4M | 143.4M |